Stanford University
Showing 29,551-29,600 of 34,412 Results
-
Joyce Teng, MD, PhD
Professor of Dermatology and, by courtesy, of Pediatrics
BioJoyce Teng, MD, PhD is a professor in dermatology at Stanford University. She is affiliated with multiple hospitals in the area, including Lucile Salter Packard Children's Hospital (LPCH) at Stanford and Stanford Hospital and Clinics (SHC). She received her medical degree from Vanderbilt University School of Medicine and has been in practice for more than 12 years. She is one of the 6 pediatric dermatologists practicing at LPCH and one of 72 at SHC who specialize in Dermatology. She sees patients with rare genetic disorders, birthmarks, vascular anomalies and a variety of inflammatory skin diseases. She is also an experienced pediatric dermatological surgeon. Her research interests are drug discovery and novel therapy for skin disorders.
-
Nelson Teng
Professor of Obstetrics and Gynecology (Oncology), Emeritus
Current Research and Scholarly InterestsGynecologic Malignancies
Immunotherapy
Biologic Response Modifiers
New Drug Development
Antigenic specificities of human antibodies encoded by the VH4-34 gene -
Valerie Teng
Clinical Associate Professor, Medicine - Primary Care and Population Health
BioDr. Valerie Teng is a board certified family physician with special interests in preventative medicine and women's health. Her experiences in caring for patients with chronic conditions, such as diabetes and hypertension, have fueled her desire to partner with patients to enter healthier lifestyles. She is also passionate about providing comprehensive care to patients of all ages, including newborns and teens.
During her residency training, Dr. Teng explored many opportunities in medical education through the O’Connor-Stanford Leaders in Education Residency (OSLER) program. She is delighted to continue in medical education as a part of the faculty at Stanford Family Medicine. -
Azusa Terasaki
Postdoctoral Scholar, Pathology
BioAzusa Terasaki, MD, PhD, is a Postdoctoral scholar in the Department of Pathology at Stanford University School of Medicine. Her research focuses on tumor immunology and cancer metabolism, with a particular interest in mitochondrial transfer between cancer and immune cells and its role in immune suppression and metastasis.
Dr. Terasaki received her medical degree and PhD in Japan, where she completed her surgical training and is a board-certified surgeon with additional certifications as a breast specialist and in cancer therapy. During her clinical career, she developed a strong interest in translational research that bridges fundamental discoveries and patient care.
Her current work investigates how cancer cells reprogram immune cells through organelle transfer, integrating imaging, flow cytometry, and multi-omic approaches to uncover novel mechanisms of tumor–immune interaction. Her goal is to identify new therapeutic targets and biomarkers to improve cancer treatment outcomes. -
Nele Marie Terveen
Affiliate, Geballe Laboratory for Advanced Materials
BioNele Marie Terveen is an Assistant Professor (Lecturer) in Innovation & Strategy at the University of Auckland, New Zealand, and is affiliated with Stanford in Professor Yi Cui's lab.
In her research, she looks at complex problems, serendipity, and innovation as well as ideation processes, specifically in the sustainability domain. She loves to explore novel phenomena through inductive and ethnographic study designs.
She aims to drive transformation at the intersection of science and practice, was invited to speak in the European Parliament for the Green Pioneers, is involved as a Fellow in the Think Tank of the Club of Rome Germany, and serves as a jury member of the Green Startup Program of the Deutsche Bundesstiftung Umwelt, as well as an ambassador of the Economy for the Common Good. -
Stefano Testa, MD
Instructor, Medicine - Oncology
BioDr. Stefano Testa is a board-certified, fellowship-trained medical oncologist with Stanford Health Care. He is also a clinical instructor in the Department of Medicine, Division of Oncology at Stanford University School of Medicine.
Dr. Testa specializes in treating patients with sarcomas and other solid tumors using cellular therapy approaches. He has expertise in adoptive T-cell therapies, including chimeric antigen receptor T-cell (CAR-T) and T-cell receptor (TCR) therapies.
As a physician-scientist, Dr. Testa focuses on developing next-generation cellular therapies for solid tumors, particularly sarcomas. His research goal is to identify targets for adoptive T-cell therapies in solid tumors, including soft tissue and bone sarcomas, and on novel synthetic biology approaches to enhance the effectiveness of T-cell therapies against solid tumors.
Dr. Testa has authored numerous peer-reviewed publications in leading medical journals, including Immunity, Cancer Discovery, JAMA Network Open, Genome Medicine, and Biomacromolecules. He has presented his research at national and international scientific meetings, including the Connective Tissue Oncology Society Annual Meeting and the Society for Immunotherapy of Cancer Annual Meeting.
Dr. Testa is a member of the American Society of Clinical Oncology (ASCO), Connective Tissue Oncology Society (CTOS), the American Society of Hematology (ASH), and the Society for Immunotherapy of Cancer (SITC). -
Jeffrey Teuteberg
Professor of Medicine (Cardiovascular Medicine)
BioHe is currently a Professor of Medicine at Stanford, but is no longer seeing patients as he is on leave and working with industry.
His research interests are in clinical outcomes in patients after transplant and mechanical support as well as novel approaches to immunosuppression. He has participated in many single-center and multi-institutional research studies and has published widely in the fields of transplant and mechanical support. He served as President of the International Society of Heart and Lung Transplantation in 2018. -
Winifred Teuteberg
Clinical Professor, Medicine - Primary Care and Population Health
BioDr. Teuteberg completed residency training in Internal Medicine at the University of Chicago and a Palliative Medicine Fellowship at Massachusetts General Hospital. She joined the faculty at Stanford in 2017 and currently sees patients as a part of the inpatient palliative care consult team at Stanford Healthcare.
She has been the clinical director or Stanford Medicine's implementation of the Ariadne Labs' Serious Illness Care Program since its inception in 2018. Her interests include communication skills training, leveraging predictive algorithms to identify patients who would most benefit from serious illness conversations, how to empower non-physician clinical team members to participate in this work, and best practice for EHR builds related to advance care planning. -
Haluk Tezcan, MD
Adjunct Clinical Associate Professor, Medicine - Oncology
BioClinical focus:
Breast Oncology
Molecular Diagnostics
Dr. Tezcan is a medical oncologist and hematologist with over three decades of diverse experience in cancer management and research.
He is leading the clinical development of Droplet Biosciences' novel liquid biopsy technology, a first-in-class lymphatic fluid molecular residual disease assessment, overseeing the scientific and clinical development of the technology. With over three decades of direct patient care and clinical trial experience as a principal investigator and director, both in academia and private practice, he has a firsthand understanding of the unmet clinical needs of physicians and patients, as well as broad experience in clinical trial design and implementation.
He is also co-principal at Athea Oncology, guiding practices and hospitals in developing clinical trial programs and high-value real-world data collection and diagnostic companies in clinical development. He is also a reviewer of JCO Precision Medicine.
Before joining Athea Oncology and Droplet Biosciences, he was the co-founder of LexentBio, which was successfully acquired by Roche/FMI. He also served as Director of Translational Medicine at Genomic Health and as Vice President, leading oncology development at Counsyl, where he integrated science with clinical product development. He established the CA.RE.foundation, a cancer research foundation dedicated to enabling the execution of clinical trials across community oncology sites throughout the Northwest US. He has independently built multiple software tools to help oncologists navigate the practical realities of their daily work.
